Renazorb is one of the common and effective Hyperphosphatemia drug available today in market
Hyperphosphatemia drugs are available in tablet form, liquid, or syrup form. Some of them are used as calcium supplements or as dialysis binders. Calcium phosphate binders are the most common type, although they may also cause hypercalcemia. Other phosphorus binders include iron-based phosphate binders, lanthanum carbonate, and calcium salts.
Iron-based
phosphate binders can help patients overcome this condition. These binders help
with the removal of excess phosphorus from the body. In addition, they are not
absorbed by the body. Thus, they are not suitable for everyone who has this
condition. However, these drugs have side effects. If hyperphosphatemia is
present in a patient, the treatment must be tailored to the individual's
condition and symptoms. In some cases, patients may have chronic kidney
disease or renal failure.
Patients
who are on dialysis or undergoing hemodialysis often experience
hyperphosphatemia. This condition can lead to serious complications and can
cause death if not treated correctly. Hyperphosphatemia Drugs help patients
maintain normal serum phosphate levels and decrease the risks of complications
associated with high phosphorus levels. Researchers are also working to develop
new medications that can treat hyperphosphatemia.
One such drug is Renazorb, which is a
proprietary nanoparticle technology that has been shown to bind phosphate. The
drug is available in liquid form and does not need to be chewed. It has been
studied in 32 healthy volunteers and showed minimal absorption in systemic
circulation. It also significantly reduced phosphate excretion in urine and
fecal fluid. The current Hyperphosphatemia
Drugs Market
Comments
Post a Comment